These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27144834)

  • 1. Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations.
    Troilo A; Benson EK; Esposito D; Garibsingh RA; Reddy EP; Mungamuri SK; Aaronson SA
    Oncotarget; 2016 May; 7(20):28765-82. PubMed ID: 27144834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
    Wang W; Li N; Li X; Tran MK; Han X; Chen J
    Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling.
    Wang H; Lu B; Castillo J; Zhang Y; Yang Z; McAllister G; Lindeman A; Reece-Hoyes J; Tallarico J; Russ C; Hoffman G; Xu W; Schirle M; Cong F
    J Biol Chem; 2016 Jul; 291(29):15256-66. PubMed ID: 27231341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
    Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
    Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
    Kulkarni A; Mohan V; Tang TT; Post L; Chan YC; Manning M; Thio N; Parker BL; Dawson MA; Rosenbluh J; Vissers JH; Harvey KF
    EMBO Rep; 2024 Sep; 25(9):3944-3969. PubMed ID: 39103676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade.
    Jia J; Qiao Y; Pilo MG; Cigliano A; Liu X; Shao Z; Calvisi DF; Chen X
    PLoS One; 2017; 12(9):e0184068. PubMed ID: 28877210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
    Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
    Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiomotin family proteins in the Hippo signaling pathway.
    Wang Y; Yu FX
    Bioessays; 2024 Aug; 46(8):e2400076. PubMed ID: 38760875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP represses the TEAD-NF-κB complex and inhibits the growth of clear cell renal cell carcinoma.
    Li Z; Su P; Yu M; Zhang X; Xu Y; Jia T; Yang P; Zhang C; Sun Y; Li X; Yang H; Ding Y; Zhuang T; Guo H; Zhu J
    Sci Signal; 2024 Jul; 17(843):eadk0231. PubMed ID: 38954637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tumor suppressor NF2 modulates TEAD4 stability and activity in Hippo signaling via direct interaction.
    Wu M; Hu L; He L; Yuan L; Yang L; Zhao B; Zhang L; He X
    J Biol Chem; 2024 May; 300(5):107212. PubMed ID: 38522513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
    Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
    Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation.
    Chan SW; Lim CJ; Guo F; Tan I; Leung T; Hong W
    J Biol Chem; 2013 Dec; 288(52):37296-307. PubMed ID: 24225952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
    Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
    Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA-binding mechanism of the Hippo pathway transcription factor TEAD4.
    Shi Z; He F; Chen M; Hua L; Wang W; Jiao S; Zhou Z
    Oncogene; 2017 Jul; 36(30):4362-4369. PubMed ID: 28368398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiomotins link F-actin architecture to Hippo pathway signaling.
    Mana-Capelli S; Paramasivam M; Dutta S; McCollum D
    Mol Biol Cell; 2014 May; 25(10):1676-85. PubMed ID: 24648494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1102-1120. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.